Cargando…
SGLT2 Inhibitors, What the Emergency Physician Needs to Know: A Narrative Review
Canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin belong to a class of antidiabetic treatments referred to as sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors, or SGLT2is). SGLT2is are currently indicated in North America and in Europe in type 2 diabetes mellitus, especially...
Autores principales: | Lu, Henri, Lu, Hortense, Kosinski, Christophe, Wojtusciszyn, Anne, Zanchi, Anne, Carron, Pierre-Nicolas, Müller, Martin, Meyer, Philippe, Martin, Jehan, Muller, Olivier, Hullin, Roger |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126052/ https://www.ncbi.nlm.nih.gov/pubmed/34068655 http://dx.doi.org/10.3390/jcm10092036 |
Ejemplares similares
-
An introduction to gender affirming healthcare: What the family physician needs to know
por: Muller, Madeleine, et al.
Publicado: (2023) -
Effects of the SGLT-2 Inhibitor Empagliflozin on Renal Tissue Oxygenation in Non-Diabetic Subjects: A Randomized, Double-Blind, Placebo-Controlled Study Protocol
por: Muller, Marie-Eve, et al.
Publicado: (2018) -
Cladribine Tablets and Relapsing–Remitting Multiple Sclerosis: A Pragmatic, Narrative Review of What Physicians Need to Know
por: AlJumah, Mohamed, et al.
Publicado: (2020) -
Hypertensive disorders of pregnancy: what the physician needs to know
por: Anthony, John, et al.
Publicado: (2016) -
Physician-Assisted Death: What Everyone Needs to Know
por: Wickline, Mary A.
Publicado: (2018)